(The service is not currently available in Greece)
- The high cost of medication can be a deterrent to patients (particularly in the case of cancer and autoimmune and rare diseases).
- State welfare / social security funds cover part of the cost of medicines. Pharmaceutical companies are coming to cover another place, leaving a fraction of the treatment to be paid by the patient.
- A patient support program (PSP) with cost-sharing is beneficial for society and for pharmaceutical companies.
- Patients who can not afford to buy expensive drugs are likely to discontinue their treatment, resulting in a deterioration in their health. Patients participating in co-funded PSPs will pay only a fraction (usually small) of the cost of the treatment.
- Companies have the opportunity to preserve or increase market share.
- The social welfare budget is better exploited.